论文部分内容阅读
目的:探讨阿托伐他汀钙在慢性心力衰竭治疗中的作用。方法:2010年1月～2011年12月于我科入院或门诊的74例慢性心力衰竭患者,随机分为阿托伐他汀钙治疗组(38例)和对照组(36例),对照组给予强心、利尿、扩血管治疗,治疗组在此基础上加用普伐他汀,剂量为20mg,每晚1次,疗程8个月,测定左室射血分数(LVEF)、左室舒张末内径(LVEDD)、左室收缩末内径(LVESD),统计2组治疗后症状改善率、再住院率、死亡率。结果:普伐他汀钠治疗组与对照组比较,治疗后2组左室射血分数均有所提高,左室收缩末内径均有缩小,但阿托伐他汀钙组明显,与对照组比较,有统计学差异;普伐他汀钠组症状改善率、心衰再住院率、死亡率下降更明显,2组比较有统计学差异。结论:阿托伐他汀钙能改善慢性心衰患者的心功能、并使患者住院率、死亡率明显下降。
Objective: To investigate the role of atorvastatin calcium in the treatment of chronic heart failure. Methods: From January 2010 to December 2011, 74 patients with chronic heart failure who were hospitalized or outpatient in our department were randomly divided into atorvastatin calcium treatment group (38 cases) and control group (36 cases), and the control group Cardiac, diuretic and vasodilator therapy were given to the treatment group. On the basis of this, pravastatin was added to the treatment group at a dose of 20 mg once a night for 8 months. Left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD) and left ventricular end-systolic diameter (LVESD). The symptom improvement rate, rehospitalization rate and death rate of two groups were calculated. Results: Compared with the control group, the left ventricular ejection fraction (LVEF) of pravastatin sodium treatment group increased after treatment and the diameter of the left ventricular end-systole decreased, but the level of atorvastatin calcium group was significantly higher than that of the control group There was a statistical difference; pravastatin sodium symptom improvement rate, heart failure rehospitalization rate, mortality decreased more significantly, the two groups were statistically significant. Conclusion: Atorvastatin calcium can improve cardiac function in patients with chronic heart failure, and make patients hospitalization rate, mortality decreased significantly.